Photothermal therapy is safe for chronic CSR

Article

Non-damaging photothermal therapy using a pattern-scanning laser (PASCAL) guided by proprietary software is a safe and effective treatment for chronic central serous retinopathy (CSR), according to a recent study.

Non-damaging photothermal therapy using a pattern-scanning laser (PASCAL) guided by proprietary software [Endpoint Management (EpM), Topcon Medical Laser Systems] is a safe and effective treatment for chronic central serous retinopathy (CSR), according to a recent study.

The study demonstrated that PASCAL with EpM was safe and improved visual acuity and resolution of subretinal fluid in chronic CSR patients. Furthermore, lack of tissue damage allowed for periodic retreatment without tissue scarring.

The study included 16 patients and demonstrated when using EpM at 30% energy level, the central macular thickness decreased, on average, from 350 μm to 282 μm (p = 0.004). In 75% of patients the subretinal fluid was completely resolved, and in 25% there was some minimal fluid left. Patients gained, on average, 12 ETDRS letters in best-corrected visual acuity at 2 months, which remained steady by 6 months of the follow-up (p

"This clinical study builds on our investigations of the heat shock protein expression after non-damaging laser therapy, and also highlights the role of the thermal stress in resolution of the CSR," said study co-author Dr Daniel Lavinsky, Federal University Rio Grande do Sul. "Since non-damaging treatment is so efficient, conventional photocoagulation may eventually be considered overtreatment."

"While traditional laser coagulation can help in treatment of macular diseases, it leaves the tissue damaged, which makes future retreatment difficult or impossible," added co-author Dr Daniel Palanker, PhD, Stanford University. "Being able to treat the retina without any damage is critical, especially for chronic diseases that require periodic re-treatments. Equally critical is being able to treat patients consistently, preserving their vision while demonstrating long-lasting therapeutic benefits."

To read the abstract of the study from the journal Retina, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.